Palvella Therapeutics (PVLA) Set to Announce Quarterly Earnings

Palvella Therapeutics (NASDAQ:PVLA) is preparing to release its quarterly earnings report on Monday, March 31, before the market opens. Analysts are predicting an earnings result of ($0.39) per share for this quarter.

Palvella Therapeutics Stock Performance

On the trading day leading up to the earnings announcement, Palvella Therapeutics shares increased by 0.9%, closing at $28.40. During this period, nearly 23,005 shares changed hands, which is below the company's average trading volume of 61,238 shares. The stock's 50-day moving average stands at $18.78, indicating a strong recent performance compared to its range over the last year. The stock has recorded a low of $6.20 and a high of $29.27 in the past fifty-two weeks. As of now, the market capitalization of Palvella Therapeutics is approximately $318.68 million. It has a negative price-to-earnings (P/E) ratio of -2.35 and a beta of 0.54.

Expert Opinions on Palvella Therapeutics

Several Wall Street analysts have recently shared their insights regarding PVLA. TD Cowen initiated coverage with a "buy" rating and set a target price of $44.00 for the stock. Similarly, Cantor Fitzgerald began their coverage with an "overweight" rating. HC Wainwright reaffirmed a "buy" rating with a target price of $38.00. Scotiabank has issued a "sector outperform" rating with a remarkable target price of $50.00, while Canaccord Genuity reiterated their "buy" rating and set a target of $39.00. Overall, five research analysts have given the stock a "buy" rating, leading to a consensus rating of "Buy" and an average target price of $42.75 for the stock.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies aimed at treating patients with serious and rare genetic skin diseases. The company, which was previously known as Pieris Pharmaceuticals Inc., is headquartered in Wayne, Pennsylvania.

Earnings, Company, Stocks